59 results
8-K
EX-99.1
CTMX
CytomX Therapeutics Inc
11 Mar 24
CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update
4:02pm
pharmacokinetic-pharmacodynamic (PK-PD) data and assessment of anti-tumor activity.
The CX-904 Phase 1a data will inform a potential decision during 2024
8-K
EX-1.1
vk0wwr3wbvvyqs4y01nv
25 Jan 21
Other Events
5:18pm